Articles by Nicolas Girard, MD, PhD
PALOMA-2 used data from PALOMA-3 to evaluate subcutaneous versus intravenous amivantamab for EGFR-mutated NSCLC.
The study is evaluating regimens to prevent dermatologic adverse events in patients receiving amivantamab plus lazertinib.
Final overall survival data from the phase 3 study demonstrated significant benefits for patients with EGFR-mutated aNSCLC.
The phase 2 trial evaluated subcutaneous amivantamab and lazertinib as a first-line therapy for EGFR-mutated NSCLC.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.